Ryan & Maniskas, LLP (www.rmclasslaw.com/cases/hgsi)
is investigating potential claims against the board of directors of
Human Genome Sciences Inc. (“Human Genome” or the “Company”) (NASDAQ:
HGSI) concerning possible breaches of fiduciary duty and other
violations of law related to the Company’s efforts to sell Human Genome
to GlaxoSmithKline plc in a transaction valued at approximately $3
Our investigation concerns possible breaches of fiduciary duty and other
violations of law related to the approval of the transaction by the
Company’s board of directors; in particular, whether the Company
undertook a fair process to obtain fair consideration for all
shareholders of Human Genome. For more information regarding our
investigation, please contact Ryan & Maniskas, LLP (Richard A. Maniskas,
Esquire) toll-free at (877) 316-3218 or by email at email@example.com
or visit: www.rmclasslaw.com/cases/hgsi.
Under the terms of the transaction, Human Genome shareholders will
receive $14.25 per share of Human Genome stock they own.
If you own shares of Human Genome and would like to learn more about
these claims or if you wish to discuss these matters and have any
questions concerning this announcement or your rights, contact Richard
A. Maniskas, Esquire toll-free at (877) 316-3218 or to sign up online,
You may also email Mr. Maniskas at firstname.lastname@example.org.
For more information about class action cases in general, please visit
our website: www.rmclasslaw.com.
Ryan & Maniskas, LLP is a national shareholder litigation firm. Ryan &
Maniskas, LLP is devoted to protecting the interests of individual and
institutional investors in shareholder actions in state and federal